Inhibrx Biosciences (INBX) Cash from Financing Activities (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Cash from Financing Activities data on file, last reported at $1.3 million in Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at $1.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $101.4 million (up 41.53% YoY), and the FY2025 annual result was $101.4 million, up 41.53% from the prior year.
• Cash from Financing Activities advanced to $1.3 million in Q4 2025 per INBX's latest filing, from $352000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $199.9 million in Q3 2023 and troughed at $352000.0 in Q3 2025.
• A 3-year average of $53.4 million and a median of $32.9 million in 2024 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 157.8% in 2025 and fell as far as 157.8% in 2025.
• A 3-year view of Cash from Financing Activities shows it stood at $860000.0 in 2023, then soared by 3731.4% to $32.9 million in 2024, then slumped by 96.19% to $1.3 million in 2025.
• Business Quant data shows INBX's Cash from Financing Activities at $1.3 million in Q4 2025, $352000.0 in Q3 2025, and $99.8 million in Q1 2025.